A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014

A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014–2019

Published:2021-08-11 Issue: Volume: Page:1-4
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Puri Pranav¹^ORCID,Cortese Denis¹²,Baliga Sujith³

Affiliation:

1. Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA

2. Center for Healthcare Delivery and Policy, Arizona State University, Scottsdale, AZ, USA

3. Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2021.1962002

Reference6 articles.

1. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

2. Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist

3. US Centers for Medicare and Medicaid Services Medicare Part B Drug Spending Dashboard. 2021. [cited 2021 Jan 21]. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartB

4. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

5. Medical Oncologists' Perceptions of Financial Incentives in Cancer Care

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma;Cancer Immunology, Immunotherapy;2023-09-21

2. Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis;Cardio-Oncology;2023-09-20

3. Cost–effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma;Immunotherapy;2023-09

4. Lost in the shadow of giants: The neglected treatment modalities in oncologic trials;Cancer;2023-08-29

5. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy;Journal of the National Comprehensive Cancer Network;2023-08